Peter K Sand1, Jon D Morrow, Tamara Bavendam, Dana L Creanga, Victor W Nitti. 1. Evanston Continence Center, Department of Obstetrics and Gynecology, Northwestern University, Feinberg School of Medicine, 1000 Central Street, Suite 730, Evanston, IL 60201, USA. p-sand@northwestern.edu
Abstract
INTRODUCTION AND HYPOTHESIS: We assessed fesoterodine efficacy and tolerability in women with overactive bladder (OAB). METHODS: This post hoc analysis of pooled data from two clinical trials included 1,548 women with OAB randomized toplacebo, fesoterodine 4 or 8 mg, or tolterodine extended release (ER) 4 mg (in 1 trial) for 12 weeks. Subjects completed 3-day bladder diaries at baseline and weeks 2 and 12 and rated Treatment Response at weeks 2 and 12. RESULTS: By weeks 2 and 12, all active-treatment groups showed significant improvements in all five bladder diary variables assessed and greater Treatment Response rates vs placebo. Fesoterodine 8 mg was significantly more efficacious than fesoterodine 4 mg and tolterodine ER in improving urgency urinary incontinence episodes and continent days per week. The most common adverse events were dry mouth and constipation, which were predominately mild or moderate. CONCLUSIONS:Fesoterodine is efficacious and well tolerated in women with OAB.
RCT Entities:
INTRODUCTION AND HYPOTHESIS: We assessed fesoterodine efficacy and tolerability in women with overactive bladder (OAB). METHODS: This post hoc analysis of pooled data from two clinical trials included 1,548 women with OAB randomized to placebo, fesoterodine 4 or 8 mg, or tolterodine extended release (ER) 4 mg (in 1 trial) for 12 weeks. Subjects completed 3-day bladder diaries at baseline and weeks 2 and 12 and rated Treatment Response at weeks 2 and 12. RESULTS: By weeks 2 and 12, all active-treatment groups showed significant improvements in all five bladder diary variables assessed and greater Treatment Response rates vs placebo. Fesoterodine 8 mg was significantly more efficacious than fesoterodine 4 mg and tolterodine ER in improving urgency urinary incontinence episodes and continent days per week. The most common adverse events were dry mouth and constipation, which were predominately mild or moderate. CONCLUSIONS:Fesoterodine is efficacious and well tolerated in women with OAB.
Authors: Paul Abrams; Linda Cardozo; Magnus Fall; Derek Griffiths; Peter Rosier; Ulf Ulmsten; Philip Van Kerrebroeck; Arne Victor; Alan Wein Journal: Urology Date: 2003-01 Impact factor: 2.649
Authors: Debra E Irwin; Ian Milsom; Steinar Hunskaar; Kate Reilly; Zoe Kopp; Sender Herschorn; Karin Coyne; Con Kelleher; Christian Hampel; Walter Artibani; Paul Abrams Journal: Eur Urol Date: 2006-10-02 Impact factor: 20.096
Authors: Vik Khullar; Eric S Rovner; Roger Dmochowski; Victor Nitti; Joseph Wang; Zhonghong Guan Journal: Urology Date: 2008-03-17 Impact factor: 2.649
Authors: K S Coyne; V Elinoff; D A Gordon; D Y Deng; M Brodsky; D B Glasser; Z Jumadilova; M Carlsson Journal: Int J Clin Pract Date: 2008-06 Impact factor: 2.503
Authors: Jaques Corcos; Richard Casey; Allan Patrick; Cal Andreou; Paula C Miceli; Joseph L Reiz; Zoltan Harsanyi; Andrew C Darke Journal: BJU Int Date: 2006-03 Impact factor: 5.588
Authors: Christopher R Chapple; Philip E Van Kerrebroeck; Klaus-Peter Jünemann; Joseph T Wang; Marina Brodsky Journal: BJU Int Date: 2008-07-21 Impact factor: 5.588
Authors: Ethan M Balk; Gaelen P Adam; Katherine Corsi; Amanda Mogul; Thomas A Trikalinos; Peter C Jeppson Journal: J Gen Intern Med Date: 2019-05-06 Impact factor: 5.128